Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Omeros Corporation OMER
$5.65
+$0.19 (3.39%)
На 18:00, 12 мая 2023
-64.60%
Потенциал через год
Ранг: 1
Ключевые показатели
-
Marketcap
354982720.00000000
-
week52high
7.75
-
week52low
1.74
-
Revenue
0
-
P/E TTM
2
-
Beta
1.09204100
-
EPS
-2.83000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B of A Securities | Neutral | Buy | 08 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 19 окт 2021 г. |
| JP Morgan | Underweight | Neutral | 08 окт 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 06 окт 2021 г. |
| Maxim Group | Hold | Buy | 04 окт 2021 г. |
| B of A Securities | Underperform | Neutral | 08 ноя 2022 г. |
| UBS | Neutral | Buy | 08 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bumol Thomas F. | A | 7500 | 7500 | 21 сент 2022 г. |
| Cable Thomas J. | A | 7500 | 7500 | 21 сент 2022 г. |
| Demopulos Peter A MD | A | 7500 | 7500 | 21 сент 2022 г. |
| Shah Rajiv | A | 7500 | 7500 | 21 сент 2022 г. |
| Zumwalt Kurt | A | 7500 | 7500 | 21 сент 2022 г. |
| Hood Leroy E. MD PhD | A | 7500 | 7500 | 21 сент 2022 г. |
| Demopulos Gregory A MD | A | 650000 | 650000 | 21 сент 2022 г. |
| HANISH ARNOLD C | A | 7500 | 7500 | 21 сент 2022 г. |
| Cancelmo Peter B | A | 80000 | 80000 | 21 сент 2022 г. |
| JACOBSEN MICHAEL A | A | 85000 | 85000 | 21 сент 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1653700 | 195532 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 1139590 | 32680 | 31 авг 2020 г. |
| iShares NASDAQ Biotechnology ETF | 627839 | 61914 | 31 авг 2020 г. |
| iShares Russell 2000 Growth ETF | 488032 | -4808 | 31 авг 2020 г. |
| Schwab U.S. Small-Cap ETF | 186745 | 726 | 31 авг 2020 г. |
| Vanguard Health Care Index Fund | 151538 | 18573 | 31 авг 2020 г. |
| Vanguard Extended Market Index Fund | 748479 | -1709 | 31 июл 2020 г. |
| TIAA-CREF Quant Small-Cap Equity Fund | 303100 | 12171 | 31 июл 2020 г. |
| Fidelity Extended Market Index Fund | 249213 | 0 | 31 июл 2020 г. |
| Fidelity Small Cap Index Fund | 306360 | 56954 | 30 апр 2020 г. |
Новостная лента
Omeros Corporation (OMER) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 22:54
Omeros Corporation (NASDAQ:OMER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and CEO Mike Jacobsen - Chief Accounting Officer Nadia Dac - Chief Commercial Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Greg Harrison - Bank of America Elliott Bosco - UBS Brandon Folkes - Cantor Fitzgerald Operator Good afternoon, and welcome to today's earnings call from Omeros Corporation. At this time, all participants are in a listen-only mode.
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
Business Wire
04 мая 2023 г. в 16:06
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via phone.
Omeros Corporation (OMER) Q4 2022 Earnings Call Transcript
Seeking Alpha
13 мар 2023 г. в 23:17
Omeros Corporation (NASDAQ:OMER ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Dr. Greg Demopulos - Chairman and CEO Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Nadia Dac - Vice President and CCO Conference Call Participants Colin Bristow - UBS Steve Brozak - WBB Securities Mary Kate - Bank of America Brandon Folkes - Cantor Serge Belanger - Needham & Company Operator Good afternoon. And welcome to today's earnings call from Omeros Corporation.
OMER Stock: Over 50% Surge Explained
Pulse2
06 февр 2023 г. в 12:36
The stock price of Omeros Corporation (NASDAQ: OMER) surged by over 50% intraday today. This is why.
Why Omeros Corporation Stock Is Skyrocketing Today
The Motley Fool
06 февр 2023 г. в 11:30
The Omeros will now be able to fund operations at least through 2025.